Chronic migraine affects approximately 148 million people worldwide and is a neurological condition that severely impacts quality of life. OnabotulinumtoxinA (Botox) received FDA approval in 2010 and its efficacy has been demonstrated through the PREEMPT trials, making it an established chronic migraine prophylaxis treatment. Migraine Botox administered at Virtuana Clinic in Izmit/Kocaeli produces significant improvement in 68% of patients who experience headaches on more than 15 days per month. In this guide you will find detailed information on PREEMPT Phase III data, the 31-point injection protocol, the CGRP mechanism, insurance coverage, and current treatment comparisons.
What Is Migraine Botox?
Migraine Botox is an FDA-approved treatment method in which onabotulinumtoxinA (Botox), a botulinum toxin type A preparation used for chronic migraine prophylaxis, is injected into specific muscles of the head and neck. The treatment reduces the frequency, duration, and severity of migraine attacks by blocking the release of neurotransmitters that transmit pain signals.
Unlike cosmetic Botox, migraine Botox is administered at a dose of 155–195 units across 31–39 injection points. While cosmetic Botox typically uses 20–60 units in total, migraine Botox requires 3–4 times that amount. Treatment is repeated every 12 weeks by a neurologist or trained physician.
| Feature | Cosmetic Botox | Migraine Botox |
|---|---|---|
| Total Dose | 20–60 units | 155–195 units |
| Injection Points | 5–15 points | 31–39 points |
| Repeat Frequency | Every 4–6 months | Every 12 weeks |
| Target | Muscle relaxation | Neurotransmitter blockade |
| FDA Approval | 2002 | 2010 |
| Onset of Effect | 3–7 days | 2–4 weeks |
What Is Chronic Migraine and How Does It Differ from Episodic Migraine?
Chronic migraine is defined as headache occurring on 15 or more days per month, with at least 8 of those days meeting migraine criteria (ICHD-3). This definition clearly distinguishes chronic migraine from episodic migraine and determines the treatment strategy.
Chronic vs Episodic Migraine Comparison
| Criterion | Episodic Migraine | Chronic Migraine |
|---|---|---|
| Headache Days/Month | < 15 days | ≥ 15 days |
| Migraine Days/Month | Variable | ≥ 8 days |
| Duration | At least 3 months | At least 3 months |
| Prevalence | 12–14% | 1.4–2.2% |
| Botox Eligibility | No | Yes |
| Medication Overuse Risk | Low | 50–80% |
| Disability Score (MIDAS) | 11–20 | 21+ |
50–80% of chronic migraine patients also present with medication-overuse headache, which develops when acute pain reliever use exceeds 10–15 days per month. The annual risk of converting to chronic migraine is 2.5%.
Chronic migraine diagnostic criteria (ICHD-3):
- Headache on 15 or more days per month for at least 3 months
- At least 8 of those days have migraine features
- Not attributable to another diagnosis
- Medication overuse has been excluded or treated
How Migraine Botox Works: The CGRP Mechanism
Migraine Botox exerts its effect by blocking the release of pain mediators — including CGRP (calcitonin gene-related peptide), substance P, and glutamate — from peripheral nerve endings. This mechanism reduces central sensitisation and breaks the cycle of chronic migraine.
The CGRP Pathway in Detail
CGRP (Calcitonin Gene-Related Peptide) is a 37-amino-acid neuropeptide produced in the trigeminal nerve system. During a migraine attack, CGRP levels increase 3–4-fold. The effects of CGRP include:
- Triggering vasodilation (dilating meningeal blood vessels)
- Initiating neurogenic inflammation
- Stimulating mast cell degranulation
- Inducing central sensitisation
- Amplifying pain signal transmission
Botulinum toxin type A cleaves the SNARE protein complex (specifically SNAP-25) at nerve endings, preventing vesicle fusion with the cell membrane. As a result:
- CGRP release is reduced by 60–70%
- Substance P release is reduced by 40–50%
- Glutamate release is blocked
- TRPV1 receptor surface expression is decreased
Peripheral and Central Mechanisms
| Mechanism | Site of Action | Outcome |
|---|---|---|
| SNAP-25 cleavage | Nerve endings | Neurotransmitter release blocked |
| CGRP blockade | Trigeminal ganglion | Neurogenic inflammation reduced |
| TRPV1 inhibition | Sensory neurons | Pain threshold elevated |
| Substance P reduction | Meningeal vessels | Vasodilation decreased |
| Central sensitisation | Trigeminal nucleus | Pain amplification reduced |
The PREEMPT Trial: Phase III Clinical Data
The PREEMPT (Phase III REsearch Evaluating Migraine Prophylaxis Therapy) programme comprises two double-blind, randomised, placebo-controlled Phase III clinical trials (PREEMPT 1 and PREEMPT 2) evaluating the efficacy of onabotulinumtoxinA in chronic migraine prophylaxis. A total of 1,384 chronic migraine patients were enrolled.
PREEMPT 1
- Patients: 679 (Botox: 341, placebo: 338)
- Primary endpoint: Number of headache episodes
- Result: No statistically significant difference in primary endpoint
- Secondary endpoints: Significant reductions in headache days, migraine days, and cumulative headache hours
PREEMPT 2
- Patients: 705 (Botox: 347, placebo: 358)
- Primary endpoint: Number of headache days in a 28-day period
- Result: −9.0 vs −6.7 days in favour of Botox (p < 0.001)
- Migraine day reduction: −8.7 vs −6.3 days (p < 0.001)
Pooled Results
| Parameter | Botox Group | Placebo Group | Difference |
|---|---|---|---|
| Headache day reduction | −8.4 days | −6.6 days | −1.8 days (p < 0.001) |
| Migraine day reduction | −8.2 days | −6.2 days | −2.0 days (p < 0.001) |
| Cumulative headache hours | −132 hours | −90 hours | −42 hours (p < 0.001) |
| HIT-6 score improvement | −4.9 points | −2.4 points | −2.5 points (p < 0.001) |
| ≥50% responder rate | 47.1% | 35.1% | 12% difference |
In the open-label extension phase (56 weeks), 70% of patients showed a ≥50% reduction in headache days.
The 31-Point Injection Protocol and Anatomical Landmarks
The PREEMPT injection protocol involves administering 155 units of onabotulinumtoxinA across 31 fixed points in 7 different head and neck muscle groups. Each injection point receives 5 units (0.1 mL).
7 Muscle Groups and Injection Points
- Corrugator (brow furrower muscle) — 2 points (bilateral) — 5 units each, total 10 units. Anatomical landmark: just above the brow origin, 1 cm above the superior orbital rim.
- Procerus (bridge of nose muscle) — 1 point (midline) — 5 units. Anatomical landmark: glabellar region, midline between the brows.
- Frontalis (forehead muscle) — 4 points (2 per side) — 5 units each, total 20 units. Anatomical landmark: 2 cm above the brow line, at pupil and lateral canthus levels. Caution: avoid injections close to the brow line to reduce risk of brow ptosis.
- Temporalis (temple muscle) — 8 points (4 per side) — 5 units each, total 40 units. Anatomical landmark: distributed along the temporal fossa from the temporal line posteriorly.
- Occipitalis (occipital muscle) — 6 points (3 per side) — 5 units each, total 30 units. Anatomical landmark: 2 cm lateral and superior to the external occipital protuberance. Caution: avoid the occipital artery and nerve.
- Cervical paraspinal muscles — 4 points (2 per side) — 5 units each, total 20 units. Anatomical landmark: C2–C4 vertebral level, 1–2 cm lateral to midline.
- Trapezius — 6 points (3 per side) — 5 units each, total 30 units. Anatomical landmark: the thickest part of the upper trapezius fibres, between the acromion and C7 vertebra.
Optional Additional Injections (Follow-the-Pain)
The physician may administer up to 40 additional units (8 additional injection points) to the temporalis, occipitalis, and/or trapezius based on the patient's individual pain distribution. In this case, the total dose becomes 195 units across 39 injection points.
| Muscle Group | Fixed Points | Fixed Dose | Optional Extra | Extra Dose |
|---|---|---|---|---|
| Corrugator | 2 | 10 U | — | — |
| Procerus | 1 | 5 U | — | — |
| Frontalis | 4 | 20 U | — | — |
| Temporalis | 8 | 40 U | +4 | +20 U |
| Occipitalis | 6 | 30 U | +2 | +10 U |
| Cervical Paraspinal | 4 | 20 U | — | — |
| Trapezius | 6 | 30 U | +2 | +10 U |
| Total | 31 | 155 U | +8 | +40 U |
The Migraine Botox Treatment Process
The migraine Botox treatment process, including assessment, takes approximately 30–45 minutes and does not require local anaesthesia. Injections are performed with a 30-gauge needle and patients can return to their daily activities on the same day.
Pre-Treatment Preparation
- Migraine diary review — Headache days from the past 3 months are evaluated
- Medication history — Acute and preventive medications are reviewed
- Contraindication screening — Pregnancy, breastfeeding, and neuromuscular diseases are checked
- Expectation management — Patient is informed about the onset timeline (2–4 weeks)
- Marking injection sites — Anatomical landmarks are identified
Treatment Steps
- Injection sites are cleaned with an alcohol-based antiseptic
- OnabotulinumtoxinA is diluted with normal saline (100 U/2 mL)
- 5 units are injected at each of the 31 fixed points using a 30G needle
- Follow-the-pain points receive additional dose if required
- Total procedure time: 15–20 minutes
Post-Treatment Instructions
- Do not rub the injection sites for the first 4 hours
- Avoid strenuous exercise for 24 hours
- Do not sleep face-down on the first night
- Apply ice for pain if needed (no more than 15 minutes)
- Schedule the next appointment 12 weeks later
Migraine Botox Outcomes and Efficacy Data
Migraine Botox reduces headache days by an average of 8–9 days per month, significantly improves HIT-6 (Headache Impact Test) scores, and enhances quality of life. Full efficacy typically emerges after 2–3 treatment cycles.
Quality of Life Improvement Data
| Parameter | Before Treatment | After 6 Months | Improvement |
|---|---|---|---|
| Headache days/month | 19.9 days | 11.5 days | −42.2% |
| HIT-6 score | 65.4 | 57.2 | −8.2 points |
| MIDAS score | 67.2 | 32.1 | −52.2% |
| Acute medication days | 13.1 days | 7.4 days | −43.5% |
| Work/school absence | 4.2 days/month | 1.3 days/month | −69% |
HIT-6 Score Interpretation:
- 36–49: Minimal impact
- 50–55: Some impact
- 56–59: Substantial impact
- 60–78: Severe impact (where chronic migraine patients typically score)
Treatment Response Rates
- ≥50% response after session 1: 23–30%
- ≥50% response after session 2: 41–47%
- ≥50% response after session 3: 58–65%
- ≥50% response after session 5: 70%+
These figures highlight the importance of evaluating efficacy only after at least 2–3 treatment cycles (6–9 months).
The Importance of a Migraine Diary
A migraine diary is a critical tool for objectively measuring treatment efficacy, identifying triggers, and assembling documentation for insurance applications. Every chronic migraine patient should keep a migraine diary for at least 3 months before starting treatment.
What to Record in a Migraine Diary
- Time of onset and duration of headache
- Pain severity (0–10 VAS scale)
- Pain location (unilateral / bilateral)
- Associated symptoms (nausea, photophobia, phonophobia, aura)
- Acute medications used and doses
- Potential triggers (sleep, stress, food, hormonal)
- Functional impact (work/school absence, daily activity limitation)
- Menstrual cycle dates (for female patients)
Digital Migraine Diary Apps
- Migraine Buddy — The most comprehensive migraine tracking app
- N1-Headache — AI-powered trigger analysis
Migraine Botox vs. Drug Therapy: A Comparison
Migraine Botox has fewer systemic side effects than oral preventive medications, eliminates the problem of adherence, and removes the burden of daily medication with a single application every 12 weeks. However, its onset of action is slower than oral medications.
| Parameter | Oral Prophylaxis | Migraine Botox |
|---|---|---|
| Frequency | Daily | Every 12 weeks |
| Onset | 2–4 weeks | 4–8 weeks |
| Adherence | 30–50% (1 year) | 85%+ |
| Systemic side effects | High | Low |
| Weight change risk | Yes (topiramate, valproate) | No |
| Cognitive effects | Yes (topiramate) | No |
| Drug interactions | Yes | Minimal |
| Efficacy (≥50% response) | 40–50% | 47–70% |
Comparison with CGRP Inhibitors
CGRP inhibitors (erenumab, fremanezumab, galcanezumab) are next-generation preventive therapies that work through mechanisms different from migraine Botox but with comparable efficacy. Anti-CGRP monoclonal antibodies reduced monthly headache days by an average of −11.5 days over 6 months, versus −7.2 days for Botox.
Detailed Comparison
| Parameter | Migraine Botox | Erenumab (Aimovig) | Fremanezumab (Ajovy) |
|---|---|---|---|
| Mechanism | SNARE/CGRP blockade | CGRP receptor blockade | CGRP ligand blockade |
| Administration | 31 injections / 12 weeks | SC 1 injection/month | SC 1 injection/month |
| Onset | 4–8 weeks | 1–4 weeks | 1–4 weeks |
| 6-month headache reduction | −7.2 days/month | −11.5 days/month | −10.8 days/month |
| Clinical experience | 14+ years | 6+ years | 6+ years |
Combination Therapy
Adding CGRP inhibitors to patients with partial response to Botox provided an additional 5.6 days (37.8%) reduction in headache days. Patients on combined treatment averaged 9.1 headache days per month. The American Headache Society has recognised CGRP monoclonal antibodies as a first-line preventive option for chronic migraine as of 2023.
Patient Selection Criteria
The ideal candidate for migraine Botox is an adult with a confirmed chronic migraine diagnosis (≥15 headache days/month, ≥8 migraine days), inadequate response to at least 2 oral preventive medications, and no contraindications.
Inclusion Criteria
- Age 18–65
- Chronic migraine diagnosis (ICHD-3)
- At least 3 months of migraine diary documentation
- Inadequate response to at least 2 oral preventive medications
- Medication-overuse headache treated or excluded
- Female patients without current pregnancy plans
Exclusion Criteria
- Episodic migraine (fewer than 15 days/month)
- Pregnancy or breastfeeding
- Neuromuscular diseases (myasthenia gravis, Lambert-Eaton)
- Active infection at injection sites
- Known allergy to botulinum toxin
- Bleeding disorders or anticoagulant therapy
Trigger Management and Botox Treatment
Migraine trigger management is a complementary approach that enhances the efficacy of Botox treatment and can additionally reduce attack frequency by 20–30%. Identifying and managing triggers significantly improves treatment success.
Major Migraine Triggers and Management Strategies
| Trigger | Prevalence | Management Strategy |
|---|---|---|
| Stress | 80% | Cognitive behavioural therapy, mindfulness |
| Sleep disruption | 50% | Consistent sleep-wake schedule |
| Hormonal changes | 65% (women) | Menstrual migraine prophylaxis |
| Weather changes | 50% | Uncontrollable — increase prophylaxis |
| Food triggers | 20–30% | Elimination diet |
| Alcohol | 35% | Avoidance |
| Caffeine withdrawal | 25% | Consistent, moderate consumption |
| Dehydration | 40% | 2–3 litres of water daily |
Treatment Failure Management
Treatment failure is defined as less than 30% reduction in headache days after at least 2 full treatment cycles (6 months). In case of failure, follow-the-pain additional doses, adding CGRP inhibitors, or alternative therapies should be considered.
Failure Management Algorithm
- Re-evaluate the diagnosis — Is the chronic migraine diagnosis correct?
- Check for medication overuse — Is acute medication use exceeding 10–15 days/month?
- Review injection technique — Is the PREEMPT protocol being followed correctly?
- Add follow-the-pain doses — Increase from 155 U to 195 U
- Add a CGRP inhibitor — Consider combination therapy
- Treat comorbidities — Depression, anxiety, sleep apnoea
- Consider neurostimulation — TENS, SPG blockade
Side Effects of Migraine Botox
Migraine Botox side effects are generally mild and transient; the most common are neck pain (6.7%), injection-site pain (3.2%), and muscle weakness (3.3%). The rate of serious adverse events is below 1%.
Side Effect Frequency Table
| Side Effect | Frequency | Duration | Management |
|---|---|---|---|
| Neck pain | 6.7% | 1–2 weeks | Paracetamol, ice |
| Injection-site pain | 3.2% | 1–3 days | Ice application |
| Muscle weakness | 3.3% | 2–4 weeks | Resolves spontaneously |
| Eyelid drooping | 1.8% | 2–6 weeks | Apraclonidine drops |
| Paradoxical headache | 2.1% | 1–3 days | Acute medication |
| Skin rash | 0.5% | 3–7 days | Antihistamine |
| Serious allergic reaction | < 0.1% | — | Emergency management |
Migraine Botox Pricing
Migraine Botox pricing varies depending on the clinic, the total dose used (155–195 units), and the product brand. Please contact us for current pricing. Coverage through private health insurance may be available — we recommend checking with your insurer.
FDA Approval Timeline
OnabotulinumtoxinA received FDA approval for the treatment of chronic migraine on 15 October 2010, based on the data from PREEMPT 1 and PREEMPT 2.
Chronology
| Year | Milestone |
|---|---|
| 2000 | First pilot studies initiated |
| 2006 | PREEMPT 1 began |
| 2007 | PREEMPT 2 began |
| 2010 (March) | PREEMPT 1 and 2 results published |
| 2010 (October) | FDA granted chronic migraine approval |
| 2011 | EMA (European Medicines Agency) approval |
| 2018 | First CGRP inhibitor (erenumab) received FDA approval |
| 2023 | AHS recommended CGRP as first-line therapy |
Frequently Asked Questions (FAQ)
1. How many sessions does migraine Botox take to work?
Migraine Botox typically reaches full efficacy after 2–3 treatment cycles (6–9 months). In the PREEMPT trials, 23–30% of patients reported ≥50% pain reduction after the first session, rising to 58–65% after the third.
2. Is migraine Botox painful?
Migraine Botox injections use a fine 30-gauge needle and most patients report no more than a mild stinging sensation. Although 31–39 injections are given in total, each is completed within seconds. Topical anaesthetic cream can be applied if desired.
3. Is migraine Botox covered by insurance?
Coverage depends on your country and insurance plan. Requirements typically include a neurologist diagnosis, at least 3 months of migraine diary, failure of at least 2 preventive medications, and treatment at a specialist centre. Private clinic applications are generally not covered. Please contact us for more information.
4. Can Botox be used for episodic migraine?
No. Migraine Botox is FDA-approved only for chronic migraine (≥15 headache days/month). Its efficacy in episodic migraine (fewer than 15 days/month) has not been proven.
5. Can migraine Botox and cosmetic Botox be done together?
Yes, both can be performed in the same session. The PREEMPT protocol's forehead and glabella injections already provide cosmetic benefit. Total dose should not exceed 200 units.
6. Can Botox be given during pregnancy?
No. Migraine Botox is contraindicated during pregnancy and breastfeeding. Women planning to conceive should wait at least 3 months after the last application.
7. Does migraine Botox cause dependence?
No. Migraine Botox does not cause physical or psychological dependence. If treatment is stopped, returning migraine frequency reflects the ongoing underlying condition, not dependence.
8. Are CGRP inhibitors or Botox more effective?
Current data indicate that CGRP inhibitors produce greater reductions in monthly headache days over 6 months (−11.5 vs −7.2 days). However, Botox has more extensive clinical experience and lower cost. Both can be used in combination.
9. Is migraine Botox permanent?
No. Each application is effective for approximately 10–12 weeks, requiring repeat every 12 weeks. However, with long-term treatment, some patients experience lasting improvement.
10. Can I exercise after migraine Botox?
Heavy exercise is not recommended for the first 24 hours due to the risk of increased toxin diffusion. Normal physical activity can resume after 24 hours.
11. Is migraine Botox used in children?
Migraine Botox is not FDA-approved for patients under 18. For paediatric chronic migraine, oral preventive medications and lifestyle changes are first-line.
12. Can I take migraine medication while receiving Botox?
Yes. Acute migraine medications (triptans, NSAIDs) and other preventive drugs may be used during Botox treatment, provided acute medication use does not exceed 10–15 days per month.
13. Which types of migraine does Botox help?
Botox is effective for chronic migraine (with or without aura), menstrual chronic migraine, and chronic migraine with medication-overuse headache. Efficacy in episodic migraine, cluster headache, and tension-type headache has not been established.
14. How long does a migraine Botox session take?
The injections take approximately 15–20 minutes. The total appointment including assessment is around 30–45 minutes.
15. When will I see results?
Effects may begin within 2–4 weeks of the first session, but full efficacy should be assessed after 2–3 treatment cycles (6–9 months).
Migraine Botox at Virtuana Clinic
Virtuana Clinic administers migraine Botox according to the PREEMPT protocol (31 points, 155–195 U) in Izmit/Kocaeli. Patients who have received a chronic migraine diagnosis from a neurologist are welcomed, and each treatment plan is individualised. For appointments and further information, please contact us through our website.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.